anxiety
Anxiety disorders — including generalized anxiety disorder (GAD), social anxiety disorder, PTSD, panic disorder, and OCD — collectively represent the most prevalent psychiatric condition globally, affecting approximately 30% of adults at some point in their lives. Despite widespread availability of SSRIs, SNRIs, and benzodiazepines, substantial proportions of patients fail to achieve remission, driving an active clinical trial landscape for novel mechanisms and delivery formats.
Active trials investigate CRHR1 antagonists for stress-induced anxiety, V1b vasopressin receptor antagonists, cannabidiol formulations, MDMA-assisted psychotherapy for PTSD (Phase 3 results showed strong efficacy in two trials), ketamine infusion for severe GAD refractory to other treatments, transcranial magnetic stimulation (TMS), and digital therapeutics combining cognitive behavioral therapy with biometric monitoring. PTSD trials often recruit veterans and first responders.
Anxiety trials typically use validated rating scales (HAM-A, GADARS, CAPS-5 for PTSD) at baseline and follow-up; prior SSRIs/SNRIs trials and current benzodiazepine use are common eligibility considerations.